TITLE

CELL PATHWAYS SIGNS PALADIN FOR APTOSYN MARKETING IN CANADA

PUB. DATE
September 2000
SOURCE
Worldwide Biotech;Sep2000, Vol. 12. Issue 9, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the marketing and distribution agreement signed by Cell Pathways Inc. with Paladin Labs.
ACCESSION #
3533626

 

Related Articles

  • R&D news.  // Pharmaceutical Executive;Nov98, Vol. 18 Issue 11, p120 

    Presents news briefs on research and development agreements in the pharmaceutical industry. Preliminary results of the Phase I/II clinical trial of GVAX vaccine for prostate cancer; Details on the clinical study on Prevatac by Cell Pathways; Information on Phase III clinical trial of INKP-100...

  • Cell Pathways' NDA Submission Accepted for Filing.  // Biotech Business;Dec99, Vol. 12 Issue 12, p1 

    Announces that the United States Food and Drug Administration has accepted Cell Pathways Incorporated's New Drug Application for Aptosyn.

  • Cell Pathways reports net loss for second quarter.  // Biotech Financial Reports;Sep99, p7 

    Reports on Cell Pathways Inc.'s posting of its financial results for the second quarter of 1999. Net loss from operations; Increase in research and development expenses; Comparison with the 1998 second quarter.

  • New pathway for Blaxland.  // Drug Topics;9/20/93, Vol. 137 Issue 18, p84 

    Reports on the appointment of Christopher Blaxland as president of Cell Pathways Inc. Company's search for chemopreventive agents for the treatment of precancerous lesions; Previous positions.

  • Cell Pathways to file NDA. Brower, Vicki // Nature Biotechnology;Aug99, Vol. 17 Issue 8, p735 

    Reports on a possible development of drug for the treatment of adenomatous polyposis coliby by Horsham, Pennsylvania-based biotechnology company Cell Pathways Inc.

  • CELL PATHWAYS REPORTS DECREASED NET LOSS FOR SECOND QTR.  // Biotech Financial Reports;Sep2001, p7 

    Focuses on financial performance of Horsham, Pennsylvania-based pharmaceutical firm Cell Pathways Inc. for second quarter ended June 30, 2001. Comparison with 2000 figures; Research and development expenses; Progress of clinical development programs.

  • Cancer Pathways' target not validated by clinical results. Ratner, Mark // Nature Biotechnology;Mar1999, Vol. 17 Issue 3, p220 

    Reports that Horsham, Pennsylvania-based Cell Pathways Inc.'s pivotal phase III trial of its product Exisulind for cancer did not achieve a significant clinical response. Decline in share prices of the company; Plan of the company to disclose the specifics of its understanding of the drug's...

  • NEW PRODUCT NEWSWIRE.  // Drug Topics;3/4/2002, Vol. 146 Issue 5, p96 

    Presents updates related to products and services in the United States pharmaceutical industry as of March 4, 2002. Agreement between Cell Pathways Inc. and Sinclair Pharma Ltd. to become an exclusive distributor of Gelclair Concentrated Oral Gel, a treatment for oncological diseases; Approval...

  • Cure Crusader. Thompson, Dick // Time;10/11/1999, Vol. 154 Issue 15, p72 

    Discusses the efforts of the late Cell Pathways pharmaceutical company founder, Floyd Nichols, to find a cure for familial adenomatous polyposis (FAP), a genetic disorder of cancerous polyps on the lining of the intestines. Studies on the aspirin-like arthritis drug called sulindac, which was...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics